Austar Lifesciences Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 964.27 million compared to CNY 1,103.98 million a year ago. Net loss was CNY 39.94 million compared to net income of CNY 45.84 million a year ago.

Basic loss per share from continuing operations was CNY 0.08 compared to basic earnings per share from continuing operations of CNY 0.09 a year ago. Diluted loss per share from continuing operations was CNY 0.08 compared to diluted earnings per share from continuing operations of CNY 0.09 a year ago.